Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sven Estenfelder"'
Autor:
Jennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, Emily A. Saunderson, Billy M. C. Jebaraj, Daniela Steinbrecher, Anna Dolnik, Tamara J. Blätte, Dan A. Landau, Jenny Saub, Sven Estenfelder, Stefan Ibach, Florence Cymbalista, Veronique Leblond, Alain Delmer, Jasmin Bahlo, Sandra Robrecht, Kirsten Fischer, Valentin Goede, Lars Bullinger, Catherine J. Wu, Daniel Mertens, Gabriella Ficz, John G. Gribben, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Publikováno v:
Haematologica, Vol 105, Iss 5 (2020)
To identify genomic alterations contributing to the pathogenesis of high-risk chronic lymphocytic leukemia (CLL) beyond the well-established role of TP53 aberrations, we comprehensively analyzed 75 relapsed/refractory and 71 treatment-naïve high-ris
Externí odkaz:
https://doaj.org/article/b6616ac47caa446b810bf72999b7a258
Autor:
Matthias C. Schulz, Jan Kowald, Sven Estenfelder, Roland Jung, Eberhard Kuhlisch, Uwe Eckelt, Ronald Mai, Lorenz C. Hofbauer, Christian Stroszczynski, Bernd Stadlinger
Publikováno v:
Frontiers in Physiology, Vol 8 (2017)
Osteoporosis is a systemic bone disease with an increasing prevalence in the elderly population. There is conflicting opinion about whether osteoporosis affects the alveolar bone of the jaws and whether it poses a risk to the osseointegration of dent
Externí odkaz:
https://doaj.org/article/b3cb9d99892845d9bcb4a49529f17110
Autor:
Eugen Tausch, Alain Delmer, Sandra Robrecht, Karlheinz Holzmann, Florence Cymbalista, Valentin Goede, Stephan Stilgenbauer, Tamara J. Blätte, Jenny Saub, Gabriella Ficz, Daniela Steinbrecher, Anna Dolnik, Hartmut Döhner, Billy Michael Chelliah Jebaraj, Stefan Ibach, Véronique Leblond, Dan A. Landau, John G. Gribben, Daniel Mertens, Jennifer Edelmann, Emily A. Saunderson, Catherine J. Wu, Sven Estenfelder, Kirsten Fischer, Lars Bullinger, Jasmin Bahlo, Michael Hallek
Publikováno v:
Haematologica
To identify genomic alterations contributing to the pathogenesis of high-risk chronic lymphocytic leukemia (CLL) beyond the well-established role of TP53 aberrations, we comprehensively analyzed 75 relapsed/refractory and 71 treatment-naive high-risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9c99c1b2b31855e80f3cb00f17fa013
http://edoc.mdc-berlin.de/22667/2/22667suppl.zip
http://edoc.mdc-berlin.de/22667/2/22667suppl.zip
Autor:
Kirsten Fischer, Sebastian Böttcher, Petra Langerbeins, Sandra Robrecht, Clemens-Martin Wendtner, Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Holger Klaproth, Matthias Ritgen, Michael Hallek, Barbara Eichhorst, Othman Al-Sawaf, Karl-Anton Kreuzer, Thomas Illmer, Stephan Stilgenbauer, Sven Estenfelder, Jasmin Bahlo
Publikováno v:
Leukemia. 33:1161-1172
Obinutuzumab (GA101) and ibrutinib show excellent efficacy for treatment of chronic lymphocytic leukemia (CLL). Preclinical investigations and a complementary safety profile were in support of testing their combined use. The exploratory CLL2-BIG-tria
Autor:
Julia, von Tresckow, Paula, Cramer, Jasmin, Bahlo, Sandra, Robrecht, Petra, Langerbeins, Anna-Maria, Fink, Othman, Al-Sawaf, Thomas, Illmer, Holger, Klaproth, Sven, Estenfelder, Matthias, Ritgen, Kirsten, Fischer, Clemens-Martin, Wendtner, Karl-Anton, Kreuzer, Stephan, Stilgenbauer, Sebastian, Böttcher, Barbara F, Eichhorst, Michael, Hallek
Publikováno v:
Leukemia. 33(5)
Obinutuzumab (GA101) and ibrutinib show excellent efficacy for treatment of chronic lymphocytic leukemia (CLL). Preclinical investigations and a complementary safety profile were in support of testing their combined use. The exploratory CLL2-BIG-tria
Publikováno v:
OncoTargets and therapy
Over the last few years, dramatic changes have occurred in the treatment of chronic lymphocytic leukemia (CLL). The current standard for young and fit patients with CLL remains chemoimmunotherapy, namely the fludarabine, cyclophosphamide, and rituxim
Autor:
Hartmut Döhner, Jasmin Bahlo, Matthias Ritgen, Michael Hallek, Anton W. Langerak, Günter Fingerle-Rowson, Michael Kneba, Kirsten Fischer, Eugen Tausch, Sandra Robrecht, Stephan Stilgenbauer, Valentin Goede, Jacques J.M. van Dongen, Sven Estenfelder
Publikováno v:
Blood. 128:3227-3227
BACKGROUND The CLL11 trial evaluated front line treatment with Clb vs. R-Clb vs. G-Clb in 781 physically unfit patients. Genomic aberrations, IGHV and TP53 mutation status are established prognostic factors in CLL, while NOTCH1, SF3B1, ATM and others
Autor:
Julia von Tresckow, Paula Cramer, Jasmin Bahlo, Sandra Robrecht, Anja Engelke, Petra Langerbeins, Anna-Maria Fink, Thomas Illmer, Holger Klaproth, Sven Estenfelder, Matthias Ritgen, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek
Publikováno v:
Blood. 128:640-640
Introduction: In chronic lymphocytic leukemia (CLL), improved anti-CD20 antibodies such as obinutuzumab (GA101) and targeted drugs, such as ibrutinib, show very good efficacy and tolerability. With the CLL2-BIG trial, the German CLL Study Group desig
Autor:
Mark S. Cragg, Andrejs Ivanov, Eugen Tausch, Emma Vilventhraraja, Tetyana Klymenko, Stephan Stilgenbauer, Sven Estenfelder, Chen Lu, Jennifer Edelmann, John G. Gribben, Stephen A. Beers
Publikováno v:
Blood. 128:971-971
The NOTCH1 gene locusencodes a cell surface receptor which is recurrently mutated in chronic lymphocytic leukemia (CLL), with a rising incidence in higher risk cases. Upon ligand-binding two cleavage events occur. As a consequence the receptor's intr
Autor:
Thomas Illmer, Anna-Maria Fink, Stephan Stilgenbauer, Jasmin Bahlo, Sven Estenfelder, Karl-Anton Kreuzer, Matthias Ritgen, Holger Klaproth, Sebastian Böttcher, Petra Langerbeins, Sandra Robrecht, Clemens-Martin Wendtner, Paula Cramer, Julia von Tresckow, Barbara Eichhorst, Michael Hallek, Anja Engelke, Kirsten Fischer
Publikováno v:
Blood. 126:4151-4151
Introduction: In chronic lymphocytic leukemia (CLL), improved anti-CD20 antibodies such as obinutuzumab (GA101) and targeted drugs, such as ibrutinib, show very good efficacy and tolerability. With the CLL2-BIG trial, the German CLL Study Group desig